Search results

Why didn't the authors conduct a full crossover design?? Did they run out of budget for the second placebo arm (sarcasm intended). @Michiel Tack is correct--the analysis should be conducted at week 4, treatment 8. This is when the RCT ends. (For whatever they were measuring that wasn't...

@strategist Thanks for posting that twitter thread (click on it for full thread). Tweet number 7 indicates that the paper probably wasn't really read. Here is the paper. Bit of an echo chamber on twitter.

.9% is about triple the prevalence of MS and about 2X the prevalence of RA. There’s maybe 15-20 drugs available for these 2 diseases combined. If the prevalence of MECFS was this high pharma would be going crazy to get drugs approved for this disease...

Intranasal mechanical stimulation.... Hmmmmmm I thought that this was a family-friendly website....

I’m wondering if perhaps the manuscript was rejected. I’m guessing it was submitted in August 2019. That’s about 7 months—long enough to do the review, make revisions and have it published.

Where is the breakthrough? Did I miss something? Looks like no suramin trial for CFS in 2020.

Article: https://www.medpagetoday.com/rheumatology/arthritis/84736

https://www.madinamerica.com/2020/02/review-cochrane-wont-publish/

Haven’t read, but how can we determine if we have capillary endothelial dysfunction?

https://www.google.com/amp/s/www.nme.com/news/music/madonna-cancels-lisbon-gig-45-minutes-before-being-due-on-stage-madame-x-tour-injury-2598940%3famp Hmmmm......Please rest Madonna.

Not necessarily a dead end—TCAs can modulate T cells— see this thread https://www.s4me.info/threads/an-investigation-into-the-modulation-of-t-cell-phenotypes-by-amitriptyline-and-nortriptyline-2019-conroy-et-al.13031/

So can we use supplements to increase Docosahexaenoyl-choline?

Except that this wasn't really the conclusion of their study. Based on reading the Results section of the abstract, the conclusion should be "We found that of four commonly used immunosuppressive agents that we tested, only MMF depolarized mitochondria, induced T-cell ROS production and...

Quite honestly, I don’t consider this hype: seems like a pretty measured comment to me. Please note that if you want to wait for a RCT study on LDN to be funded, conducted, have data analyzed and published, please be prepared to wait at least 5 years.

Here is the link to the newsletter https://cortene.wordpress.com/2020/01/ I don't think that they would be proceeding if the drug had demonstrated no positive effect.

Interesting. I remember discussion about amitrip. on the Howard Bloom thread here—the MECFS guy that does 700 pushups.

https://www.cell.com/cell-metabolism/pdfExtended/S1550-4131(18)30573-4 Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in b Cells Haven’t read either, but wonder if oligomerization results from overexpression.

Sh*t—well it is still under consideration for macular degeneration—phase 2.

Interesting. What was your treatment @Woolie? Thanks

Thanks. But T cells still come back after Campath treatment. These new T cells are less likely to be “problematic” like the old ones were because the reconstituted T cells are different/better? https://www.jimmunol.org/content/191/12/5867...